Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Theravance Biopharma, Inc.
A biopharmaceutical company that makes YUPELRI (revefenacin), a once-daily nebulized medicine that helps people with COPD breathe more easily, sold in the US with partner Viatris. It grew out of Theravance, Inc., founded in 1996, which split in 2014 into two public companies, with Theravance Biopharma keeping the respiratory drug pipeline. Its name blends "therapy" and "advance"—fitting for a firm built on advancing medicine.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
5.07 Submission of Matters to a Vote of Security Holders
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
8.01 Other Events
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 2.05 Costs Associated with Exit or Disposal Activities · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits